Navigation Links
/C O R R E C T I O N -- Rosetta Genomics Ltd/
Date:5/21/2008

e first quarter of 2008 was $3.7 million (including a non-cash expense of $191,000 related to stock based compensation), compared with an operating loss of $2.2 million (including a non-cash expense of $205,000 related to stock based compensation) for the corresponding quarter of 2007. Net loss for the first quarter of 2008 was $3.9 million, or $0.33 per ordinary share, compared with a net loss of $2 million, or $0.23 per ordinary share, for the corresponding quarter of 2007.

Research and development expenses of $2.4 million for the first quarter of 2008, compared to $1.2 million for the first quarter of 2007, remain the Company's largest expense and accounted for 64% of its operating losses.

As of March 31, 2008 we had $18.6 million in cash, cash equivalents, short and long term bank deposits and marketable securities. Our outlook of total cash usage for operating activities for the next nine month of 2008 is approximately $10 million.

As previously announced, the Company continues to receive interest payments from its auction rate securities, which all but two are rated AAA. However, due to the continuing uncertainty in the credit market, the company recorded an impairment of $300,000 during the first quarter.

Recent Highlights

Rosetta Genomics reports the following scientific and corporate highlights:

Diagnostic Programs

- Squamous vs. Non Squamous non-small cell lung cancer (NSCLC) - Columbia University Medical Center's Molecular Pathology Laboratory has submitted this test, designed to differentiate squamous from non squamous non-small cell lung cancer (NSCLC) using a single microRNA, for regulatory approval to the New York State Department of Health. The approval process is estimated to take 2-6 months.

The ability of physicians to accurately differentiate squamous from non-squamous NSCLC is an important treatment guide. Bevacizumab, an angiogenesis inhibitor and an important new modality of therapy for n
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer and ... production capability to serve biotechnology pharmaceutical clients. A ... continues to drive Nitto Avecia to enhance synthesis ... , In Fall 2014, Nitto Avecia first ... its Milford, MA facility, which is recognized as ...
(Date:4/30/2015)... 30, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... of biosimilar therapeutics including high value and difficult ... its previously announced underwritten public offering of 6,750,000 ... offering price of $15.50 per share. This includes ... their option to purchase up to 750,000 additional ...
(Date:4/30/2015)... FRANCE (PRWEB) April 30, 2015 ... and at http://www.lespausa.com , Phytomer’s DOUCEUR ... sensitive and reactive skin while battling the weakening ... This restorative cream is formulated with star ingredient ... via biotechnology in a complex of soothing minerals ...
(Date:4/29/2015)... 29, 2015 SPIE DSS, ... on the East Coast, reaffirmed its value last week ... developers, and industry suppliers to meet and advance the ... applications. , The event included 55 conferences in two ... sensing and imaging -- and an exhibition showcasing 382 ...
Breaking Biology Technology:Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3SPIE DSS provides venue for collaboration vital to research, applications advances 2SPIE DSS provides venue for collaboration vital to research, applications advances 3SPIE DSS provides venue for collaboration vital to research, applications advances 4
... Technology, Inc. ("ACT"; OTC Bulletin Board: ACTC ... announced today that Gary Rabin, the company,s interim chairman ... BIO-Europe Spring 2011 Conference, March 14-16, at the Milano ... scheduled for Wednesday, March 16, at 10:15 a.m. CET, ...
... --Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI ... medicine, modernized traditional Chinese medicine, branded generics and other ... Annual OC Growth Stock Conference from March 13 - ... California. Dr. James Jiayuan Tong, Chief Financial ...
... 2011 BioSpecifics Technologies Corp. (Nasdaq: BSTC ; ... products, today announced its financial results for the fourth quarter ... "2010 was an exciting year for the Company, but we ... to sales growth of XIAFLEX® in the U.S., as well ...
Cached Biology Technology:ACT Interim Chairman and CEO Gary Rabin to Present at BIO-Europe Spring 2011 Conference 2TPI Attends 23rd ROTH Annual OC Growth Stock Conference from March 13-16, 2011 2BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 2BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 4BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 5BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 6BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 7
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... This press relase is available in Spanish ... coloration of pickles, skin during fermentation may actually help ... a U.S. Department of Agriculture (USDA) study. ... when combined with tartrazine, a yellow food-coloring agent used ...
... of a portion of the tuberculosis genome that responds to ... Tiwari to zero in on a network of genes that ... cause tuberculosis (TB), Mycobacterium tuberculosis, can transition into a dormant ... system. A new report from Igoshin and Tiwari in this ...
... 2010 Science in Society Journalism Awards, sponsored by the National ... In the Book category, Susan Cohen and Christine Cosgrove for ... Medical Industry,s Quest to Manipulate Height" (Tarcher/Penguin). In ... Associated Press and the New York Times. Martha Mendoza and ...
Cached Biology News:Pickle spoilage bacteria may help environment 2Study finds possible 'persistence' switch for tuberculosis 2Study finds possible 'persistence' switch for tuberculosis 3Science in Society Journalism Award winners announced 2Science in Society Journalism Award winners announced 3
BD BioCoat Collagen IV 150 mm Culture Dishes...
...
...
... are derived from the Spodoptera frugiperda Sf21 cell ... in transfections, plaque assays, virus production, and protein ... that optimizes recovery of viable cells after thawing. ... Insect Cell Medium and can also be grown ...
Biology Products: